Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts give Bicara a consensus recommendation of "Moderate Buy" (8 buys, 3 holds, 1 sell) with an average 12‑month price target of $28.
• BCAX opened at $22.98 (up 3.8%), has a market cap of $1.5B and a 12‑month range of $7.80–$23.16; the company reported Q1 EPS of ($0.68), beating estimates of ($0.72) by $0.04.
• Insider selling accelerated in March—both the COO and CEO sold shares—and insiders have sold 137,969 shares worth about $2.59M over the past 90 days.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twelve brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $28.00.

A number of equities research analysts have recently issued reports on the stock. BTIG Research reiterated a "buy" rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Citizens Jmp restated a "market outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Mizuho upgraded Bicara Therapeutics to a "hold" rating in a research report on Thursday, December 18th. Finally, Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 31st.

Bicara Therapeutics Trading Up 3.8%

BCAX stock opened at $22.98 on Wednesday. The firm has a 50 day moving average of $18.15 and a 200-day moving average of $17.41. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $23.16. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -9.08 and a beta of -1.23.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.04. Sell-side analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total transaction of $315,838.72. Following the completion of the transaction, the chief operating officer directly owned 205,141 shares in the company, valued at $3,725,360.56. The trade was a 7.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the transaction, the chief executive officer owned 339,392 shares of the company's stock, valued at $6,506,144.64. This represents a 9.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 137,969 shares of company stock valued at $2,586,198.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG grew its stake in Bicara Therapeutics by 0.9% in the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company's stock worth $2,165,000 after acquiring an additional 1,171 shares during the period. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after acquiring an additional 1,233 shares during the period. Mariner LLC grew its stake in Bicara Therapeutics by 3.0% in the 4th quarter. Mariner LLC now owns 64,562 shares of the company's stock worth $1,087,000 after acquiring an additional 1,902 shares during the period. Invesco Ltd. grew its stake in Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company's stock worth $157,000 after acquiring an additional 1,962 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics in the 4th quarter worth approximately $45,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.